TEYI PHARMACEUTICAL GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.52 CNY | -0.10% |
|
-2.36% | -25.62% |
| Apr. 19 | Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 29 | Teyi Pharmaceutical Group Co.,Ltd Approves the Cash Dividend for 2023 | CI |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 52% by 2026.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Weaknesses
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -25.62% | 672M | - | - | |
| +34.35% | 705B | C+ | ||
| +30.90% | 583B | B | ||
| -3.49% | 364B | C+ | ||
| +20.15% | 332B | B- | ||
| +6.19% | 291B | C+ | ||
| +15.04% | 238B | B+ | ||
| -3.07% | 210B | A+ | ||
| +10.53% | 209B | B- | ||
| +9.21% | 169B | C+ |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 002728 Stock
- Ratings Teyi Pharmaceutical Group Co.,Ltd